Posted On: 08/13/2014 3:46:15 PM
Post# of 30067
If the CLIA Partner is different than the General Partner after FDA approval, it may not want to pay us much up front money. If that is the case, and we don't get anything significant, shareholders will once again be disappointed and there will be a sell off.
AMBS is paying Aimee to keep abreast of what shareholders are thinking. She should be keeping in touch with the message boards enough to know that shareholders are expecting a JV by the end of summer, that will pay large up front money.
When Gerald said to me regarding a Lympro partner in Las Vegas: "Someone that offers to pay x now might be willing to pay 100x down the road." I know that I have been expecting the 100x by the end of this summer. Gerald should clear up our expectations! If we only get 1 million dollars from our CLIA Lab, that is very different than getting 35 million from Johnson & Johnson.
AMBS is paying Aimee to keep abreast of what shareholders are thinking. She should be keeping in touch with the message boards enough to know that shareholders are expecting a JV by the end of summer, that will pay large up front money.
When Gerald said to me regarding a Lympro partner in Las Vegas: "Someone that offers to pay x now might be willing to pay 100x down the road." I know that I have been expecting the 100x by the end of this summer. Gerald should clear up our expectations! If we only get 1 million dollars from our CLIA Lab, that is very different than getting 35 million from Johnson & Johnson.
(0)
(0)
